Abstract 987P
Background
We aimed to evaluate the safety and efficacy of lenvatinib in Korean population under real-world practice.
Methods
Patients were prospectively entered at 29 clinical sites through an observational post-marketing study in Korea, funded by Eisai. Patients were treated with lenvatinib according to the approved indication of uHCC. For safety analysis, Adverse Drug Reactions (ADRs) were collected. ADR was defined as AEs where the causal relationship with lenvatinib was not 'unlikely'. The efficacy was assessed by investigators as completed response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Objective response rate (ORR) was defined as CR or PR in the efficacy analysis set. Statistical analysis was conducted to identify which demographic and clinical factors were related to ORR.
Results
658 patients were included in the safety analysis set. The mean daily dose was 7.8mg/day and 10.1mg/day in patients with a body weight of < 60kg and ≥ 60kg. The relative dose intensity related to tolerance was 97% and 84%, respectively. ADRs > grade 3 were reported in 1% (8/658). The most common ADRs > grade 3 were ‘palmar-plantar erythrodysaesthesia syndrome’ (0.3%, 2/658). In the efficacy analysis set, 513 patients were included. The results were as follows: CR, 1% (5/513); PR, 13% (66/513); SD, 45% (231/513); and PD, 41% (211/513). Among the demographic and clinical factors, ORR was significantly different depending on the total treatment duration (p <0.001).
Table: 987P
Objective response rate n (%) | No. of Subjects n (%) | p-value | |
Total treatment duration | |||
< 3 months | 12 (6) | 191 (38) | <0.001 |
3 months ∼ < 6 months | 21 (13) | 165 (32) | |
6 months ∼ < 9 months | 15 (19) | 78 (15) | |
9 months or above | 23 (30) | 76 (15) | |
Total | 71 (14) | 510 (100) |
Conclusions
Lenvatinib in Korean patients with uHCC was generally well tolerated. The efficacy of treatment varied significantly with regards to the total treatment duration. Patients with longer treatment duration showed higher ORR.
Clinical trial identification
E7080-M082-509
Editorial acknowledgement
We acknowledge the significant contribution of Prof. Kang in reviewing abstract.
Legal entity responsible for the study
Eisai Korea and the authors.
Funding
Eisai.
Disclosure
J.J. Kim: Other, Institutional, Project Lead: Eisai Korea. All other authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18